Yesterday, Aug. 31, 2015, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $889.92 to $16,133,353.20.

Highlighted Stocks Traded by Insiders:

National Health Investors (NHI) - FREE Research Report

Mccabe Robert A Jr, who is Director at National Health Investors, bought 310 shares at $56.21 on Aug. 31, 2015. Following this transaction, the Director owned 7,965 shares meaning that the stake was boosted by 4.05% with the 310-share transaction.

The shares most recently traded at $54.77, down $1.44, or 2.63% since the insider transaction. Historical insider transactions for National Health Investors go as follows:

  • 4-Week # shares bought: 7,200
  • 4-Week # shares sold: 5,950
  • 12-Week # shares bought: 7,700
  • 12-Week # shares sold: 5,950
  • 24-Week # shares bought: 9,665
  • 24-Week # shares sold: 5,950

The average volume for National Health Investors has been 224,300 shares per day over the past 30 days. National Health Investors has a market cap of $2.1 billion and is part of the financial sector and real estate industry. Shares are down 21.24% year-to-date as of the close of trading on Monday.

National Health Investors Inc. is a real estate investment trust. It invests in the real estate markets of United States. The firm invests in the health care properties primarily in the long-term care and senior housing industries. The stock currently has a dividend yield of 6.01%. The company has a P/E ratio of 17.8. Currently, there is 1 analyst who rates National Health Investors a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NHI - FREE

TheStreet Quant Ratings

rates National Health Investors as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

National Health Investors Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Suffolk Bancorp (SUBK) - FREE Research Report

Orsino Michael R, who is Evp & Clo at Suffolk Bancorp, bought 500 shares at $26.36 on Aug. 31, 2015. Following this transaction, the Evp & Clo owned 16,971 shares meaning that the stake was boosted by 3.04% with the 500-share transaction.

The shares most recently traded at $26.49, up $0.13, or 0.49% since the insider transaction. Historical insider transactions for Suffolk Bancorp go as follows:

  • 4-Week # shares bought: 1,000
  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 1,900

The average volume for Suffolk Bancorp has been 25,500 shares per day over the past 30 days. Suffolk Bancorp has a market cap of $310.7 million and is part of the financial sector and banking industry. Shares are up 17.39% year-to-date as of the close of trading on Monday.

Suffolk Bancorp operates as the holding company for Suffolk County National Bank that provides commercial and retail banking services primarily in Nassau and Suffolk counties, New York. The company's deposit products include demand, saving, N.O.W., money market, and time deposits. The stock currently has a dividend yield of 1.52%. The company has a P/E ratio of 18.3. Currently, there is 1 analyst who rates Suffolk Bancorp a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUBK - FREE

TheStreet Quant Ratings

rates Suffolk Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Suffolk Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exponent (EXPO) - FREE Research Report

Corrigan Catherine, who is Group Vice President at Exponent, sold 3,000 shares at $42.27 on Aug. 31, 2015. Following this transaction, the Group Vice President owned 38,520 shares meaning that the stake was reduced by 7.23% with the 3,000-share transaction.

The shares most recently traded at $42.44, up $0.17, or 0.39% since the insider transaction. Historical insider transactions for Exponent go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 16,880
  • 24-Week # shares sold: 25,410

The average volume for Exponent has been 124,100 shares per day over the past 30 days. Exponent has a market cap of $1.1 billion and is part of the services sector and diversified services industry. Shares are up 3.64% year-to-date as of the close of trading on Monday.

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. It operates in two segments, Engineering and Other Scientific; and Environmental and Health. The stock currently has a dividend yield of 1.4%. The company has a P/E ratio of 27.7. Currently, there is 1 analyst who rates Exponent a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPO - FREE

TheStreet Quant Ratings

rates Exponent as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Exponent Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.